Original Article

You have full text access to this OnlineOpen article

Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma†‡

A report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group

  1. Howard M. Katzenstein MD1,§,*,
  2. Kay W. Chang MD2,
  3. Mark Krailo PhD3,
  4. Zhengjia Chen PhD4,
  5. Milton J. Finegold MD5,
  6. Jon Rowland MD, PhD6,
  7. Marleta Reynolds MD7,
  8. Alberto Pappo MD5,
  9. Wendy B. London PhD8,
  10. Marcio Malogolowkin MD9

Article first published online: 7 OCT 2009

DOI: 10.1002/cncr.24667

Issue

Cancer

Cancer

Volume 115, Issue 24, pages 5828–5835, 15 December 2009

Additional Information

How to Cite

Katzenstein, H. M., Chang, K. W., Krailo, M., Chen, Z., Finegold, M. J., Rowland, J., Reynolds, M., Pappo, A., London, W. B. and Malogolowkin, M. (2009), Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma. Cancer, 115: 5828–5835. doi: 10.1002/cncr.24667

Author Information

  1. 1

    Department of Pediatrics, Aflac Cancer Center of Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia

  2. 2

    Department of Otolaryngology, Lucile Packard Children's Hospital at Stanford, Palo Alto, California

  3. 3

    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California

  4. 4

    Group Operations Center, Children's Oncology Group Statistics and Data Center, Arcadia, California

  5. 5

    Departments of Pathology and Hematology/Oncology, Texas Children' Cancer Center, Baylor College of Medicine, Houston, Texas

  6. 6

    Department of Pathology, Children's Hospital of Oakland, Oakland, California

  7. 7

    Department of Surgery, Northwestern University and Children's Memorial Hospital, Chicago, Illinois

  8. 8

    Department of Statistics, University of Florida, Children's Oncology Group Data Center, Gainesville, Florida

  9. 9

    Department of Pediatrics, Children's Hospital, Los Angeles, California

  1. §

    Fax: (626) 445-4334

*Children's Oncology Group, 440 East Huntington Drive, Suite 400, Arcadia, CA 91066

  1. †

    See editorial on pages 5623–6, this issue.

  2. ‡

    We are extremely grateful for the hard work and diligence of the clinical research associates of our member institutions for data collection and to the Children' Oncology Group Publications Office for editorial assistance.

Publication History

  1. Issue published online: 2 DEC 2009
  2. Article first published online: 7 OCT 2009
  3. Manuscript Accepted: 13 MAR 2009
  4. Manuscript Revised: 11 MAR 2009
  5. Manuscript Received: 30 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (203K)

References

  • 1
    Douglass EC, Reynolds M, Finegold M, et al Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993; 11: 96-99.
  • 2
    Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group. J Clin Oncol. 1991; 9: 2167-2176.
  • 3
    Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991; 9: 1050-1058.
  • 4
    Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a Pediatric Oncology Group phase II study. J Clin Oncol. 2002; 20: 3438-3444.
  • 5
    Dall'Igna P, Cecchetto G, Dominici C, et al. Carboplatin and doxorubicin (CARDOX) for nonmetastatic hepatoblastoma: a discouraging pilot study. Med Pediatr Oncol. 2001; 36: 332-334.
    Direct Link:
  • 6
    Mollman JE, Glover DJ, Hogan WM, et al. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer. 1988; 61: 2192-2195.
    Direct Link:
  • 7
    Wadler S, Beitler JJ, Rubin JS, et al. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study. J Clin Oncol. 1993; 11: 1511-1516.
  • 8
    Malogolowkin M, Katzenstein HM, Krailo M, et al. Intensive versus standard platinum therapy for the treatment of children with hepatoblastoma (HB): a report of the Intergroup Hepatoblastoma Study P9645 [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 799. Abstract 8516.
  • 9
    Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005; 104: 841-847.
    Direct Link:
  • 10
    Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004; 40: 2445-2451.
  • 11
    Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991; 19: 295-300.
    Direct Link:
  • 12
    Bishop YMM, Feinberg SE, Holland PMW. Discrete Multivariate Analysis. Cambridge, Mass: MIT Press; 1975.
  • 13
    Armitage P, Berry G. Statistical Methods in Medical Research. Palo Alto, Calif: Blackwell Scientific; 1998.
  • 14
    Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons, Inc; 1980.
  • 15
    Malogolowkin MH, Katzenstein H, Krailo MD, et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol. 2006; 24: 2879-2884.
  • 16
    Koukourakis MI. Amifostine: is there evidence of tumor protection? Semin Oncol. 2003; 30: 18-30.
  • 17
    Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996; 14: 2101-2112.
  • 18
    Fisher MJ, Lange BJ, Needle MN, et al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer. 2004; 43: 780-784.
    Direct Link:
  • 19
    Petrilli AS, Oliveira DT, Ginani VC, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol. 2002; 24: 188-191.
  • 20
    Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008; 26: 3749-3755.
View Full Article (HTML) Get PDF (203K)